



Reflecting on the past twenty years, today and as we look forward, we remain deeply committed to *Patients First*, and both the education of patients, families and physicians and research to improve access to care, more effective treatments, improved quality of life and curative therapies.

- Valerie Slee, RN, BSN, Board Chair

Dear Friends,

In 2021, we have continued our growth and expanding outreach and access to mast cell disease education, resources and support to over 15,000 patients and caregivers. TMS is committed to being the messengers of inspirational patient experience and effect measurable changes in recognition, diagnosis, testing, and treatment of all forms of mast cell disease, with transformative improvements in quality of life for our patients and families.

The Board adopted a three-year strategic plan to boldly grow our organization and impact through six core pillars: Patient Programs, Physician Education, Research Grant Making, Patient Centered Research, Advocacy & Collaborations, and Governance & Financial Sustainability. Our strategic pillars are grounded by our mission and developed based on a series of interviews from patients, caregivers, volunteers, stakeholders and our recent needs assessment involving approximately 9,000 members to address increased patient impact and commitment to growth objectives. This strategic plan embodies our continuing commitment to listen to the diverse voices of our community, strengthen our partnerships with other organizations, and share findings and benefits from our work.

TMS & The American Academy of Allergy, Asthma & Immunology (AAAAI) granted \$60,000 to Dr. Daniel Dwyer with Brigham and Women's Hospital, Boston, MA to advance "single-cell characterization of cutaneous mast cells in mastocytosis and hereditary alpha-tryptasemia. As research grantmaking is one of our core pillars, we plan to allocate up to 25% of unrestricted net revenue to support the funding of research grants on an annual basis.

2022 brings expansion of our organization and programs aiming to educate both patients and physicians on mast cell diseases. Through continued collaboration, we have the potential and will create lasting change to serve the community and advance research of mast cell disease.

Lauren Denton, MA
Executive Director

Valerie M. Slee, RN, BSN
Chair, Board of Directors

Our IMPACT



Network of over 15,000



Adopted 3 Year Strategic Plan



32 Virtual Support Groups



1,000+ attendees at 24th National Conference (US & 15 Countries)



1,000 Nurse Line Email Support



FDA Patient Listening Session on Mastocytosis



12 Patient Voice Forums



Patient Perspective Publication on mast cell activation symptoms



COVID-19 Impact/Needs Assessment Surveys



Granted \$40,000 towards research and education

2021 Financial Summary

Assets

Cash and cash equivalents \$758,959
 Investments \$250,787
 Other Current Assets \$18,960
Total Assets \$1,028,705

Liabilities & Net Assets

Accounts Payable \$7,165
 Unrestricted Assets \$838,868
 Restricted Assets \$182,672
Total Net Assets \$1,021,540
Total Liabilities & Net Assets \$1,028,705

Revenue

Unrestricted \$361,456
 Temporarily Restricted \$165,745
 Interest and Other Income \$14,987
 Unrealized Gain on Investment \$150,447
Total Revenue \$560,928

Expenses

Admin & General \$191,467
 Program Services \$89,177
 Fundraising \$6,770
Total Expenses \$287,413
Change in Net Assets \$256,346

TMS undergoes an annual audit conducted by an independent firm. Figures are based upon the report of DeLeon and Stang CPAs & Advisors. *2021 currently undergoing CPA review.

2021 Board of Directors

Chair Valerie Slee, Vice Chair of Education and Patient Support Jan Hempstead, Vice Chair of Community Engagement Courtney Rabb, Vice Chair Research Celeste Finnerty, Interim Treasurer Rose Schultz, Secretary Judith Emmel.

2021-2023 Medical Advisory Board

Ivan Alvarez-Twose, Marla Barkoff, Patrizia Bonadonna, Joseph Butterfield, Mariana Castells, Tracy I. George, Jason Gotlib, Matthew Hamilton, Olivier Hermine, Nicholas Kounis, Anne Maitland, Larry Schwartz, Theoharis Theoharides, Celalettin Ustun, Peter Valent, Srđan Verstovsek. Honorary: K. Frank Austen, Luis Escribano.



The Mast Cell Disease Society, Inc. (TMS)
 P.O. Box 416, Sterling, MA 01564
www.tmsforacure.org